BR-01T is under clinical development by Brise Pharmaceuticals and currently in Phase I for Chronic Low Back Pain (CLBP). According to GlobalData, Phase I drugs for Chronic Low Back Pain (CLBP) have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BR-01T’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BR-01T overview
BR-01T is under development for the treatment of chronic low back pain (CLBP). The therapeutic candidate is administered through parenteral route and acts by targeting tropomyosin receptor kinase A (Trk A).
Brise Pharmaceuticals overview
Brise Pharmaceuticals (Brise Pharma) is a clinical-stage biopharmaceutical company that develops therapies to treat acute and chronic pain conditions. The company’s pipeline includes BRT01T for the treatment of chronic low back pain (CLBP); and BR005 for acute and preventive treatment of migraine. It is also developing drug programs such as BR007 to treat Camurati-Engelmann disease (CED); BR008 for the treatment of chronic neuropathic pain; and BR009 for the preventive treatment of migraine. The company was funded by Qiming Venture, Cnfuel Capital, BioTrack Capital, and Shunxi Fund, among others. Brise Pharma is headquartered in Shanghai, China.
For a complete picture of BR-01T’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
